The current states of anlotinib and its prospect in advanced oral squamous cell carcinoma

doi:10.3877/cma.j.issn.1674-1366.2020.05.009

Abstract

Abstract:

Patients with advanced oral squamous cell carcinoma often show short survival time and poor prognosis. Because of the poor efficacy of surgery, drug resistance and adverse events etc., the quality of life of these patients are required to improved by novel drugs with safety and efficacy. Anlotinib is a domestic small-molecule tyrosine kinase inhibitor, which has been presently regarded as a potential medicine for multiple advanced malignances. It targets multiple angiogenetic factor receptors to suppress the angiogenesis and inhibit partial functions of tumor cells. This review will focus on the mechanism, research status of anlotinib and its potential efficacy in advanced oral squamous cell carcinoma.

Key words: Carcinoma, squamous cell, Vasculare endothelial growth factors, Anlotinib, Angiogenesis, Chemotherapy

Chen Chu, Yan Sun, Wei Shang, Xiaochun Zhang, Shengyou Ge. The current states of anlotinib and its prospect in advanced oral squamous cell carcinoma[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2020, 14(05): 325-329.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhkqyxyjzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1366.2020.05.009

https://zhkqyxyjzz.cma-cmc.com.cn/EN/Y2020/V14/I05/325

Figures/Tables 3

References 47

[1]	Cheraghlou S, Schettino A, Zogg CK，et al. Changing prognosis of oral cancer：An analysis of survival and treatment between 1973 and 2014[J]. Laryngoscope，2018，128(12): 2762-2769. DOI: 10.1002/lary.27315.
[2]	Hsieh MY, Chen G, Chang DC，et al. The Impact of Metronomic Adjuvant Chemotherapy in Patients with Advanced Oral Cancer [J]. Ann Surg Oncol，2018，25(7): 2091-2097. DOI: 10.1245/s10434-018-6497-3.
[3]	金晶，叶茂昌，王来平，等. TPF方案诱导化疗口腔癌后Ⅳ度骨髓抑制的临床分析[J].上海口腔医学，2014，23(2): 219-223.
[4]	尚伟，郑家伟.口腔及口咽癌新版TNM分期与NCCN诊治指南部分解读[J].中国口腔颌面外科杂志，2018，16(6): 533-546. DOI: 10.19438/j.cjoms.2018.06.010.
[5]	Shen G, Zheng F, Ren D，et al. Anlotinib：a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol，2018，11(1): 120. DOI: 10.1186/s13045-018-0664-7.
[6]	Nowak-Sliwinska P, Alitalo K, Elizabeth A，et al. Consensus guidelines for the use and interpretation of angiogenesis assays [J]. Angiogenesis，2018，21(3): 425-532. DOI: 10.1007/s10456-018-9613-x.
[7]	Ochiya T, Takenaga K, Endo H. Silencing of S100A4，a metastasis-associated protein，in endothelial cells inhibits tumor angiogenesis and growth[J]. Angiogenesis，2014，17(1): 17-26. DOI: 10.1007/s10456-013-9372-7.
[8]	Zirlik K, Duyster J. Anti-Angiogenics：Current Situation and Future Perspectives[J]. Oncol Res Treat，2018，41(4): 166-171. DOI: 10.1159/000488087.
[9]	Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited：Is there a role for combinations with immunotherapy？[J]. Angiogenesis，2017，20(2): 185-204. DOI: 10.1007/s10456-017-9552-y.
[10]	Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy，chemotherapy and immunotherapy in cancer treatment[J]. International Journal Of Nanomedicine，2018，13: 6049-6058. DOI: 10.2147/IJN.S140462.
[11]	He C, Wu T, Hao Y. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway[J]. Biochem Biophys Res Commun，2018，503(4): 3093-3099. DOI: 10.1016/j.bbrc.2018.08.098.
[12]	Liang L, Hui K, Hu C，et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells[J]. J Exp Clin Cancer Res，2019，38(1): 71. DOI: 10.1186/s13046-019-1093-3.
[13]	Xie C, Wan X, Quan H，et al. Preclinical characterization of anlotinib，a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci，2018，109(4): 1207-1219. DOI: 10.1111/cas.13536.
[14]	Lin B, Song X, Yang D，et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2，PDGFRbeta and FGFR1[J]. Gene，2018，654: 77-86. DOI: 10.1016/j.gene.2018.02.026.
[15]	Ruan X, Shi X, Dong Q，et al. Antitumor effects of anlotinib in thyroid cancer[J]. Endocr Relat Cancer，2019，26(1): 153-164. DOI: 10.1530/ERC-17-0558.
[16]	Sun Y, Niu W, Du F，et al. Safety，pharmacokinetics，and antitumor properties of anlotinib，an oral multi-target tyrosine kinase inhibitor，in patients with advanced refractory solid tumors[J]. J Hematol Oncol，2016，9(1): 105. DOI: 10.1186/s13045-016-0332-8.
[17]	Miller KD, Nogueira L, Mariotto AB，et al. Cancer treatment and survivorship statistics，2019[J]. CA Cancer J Clin，2019，69(5): 363-385. DOI: 10.3322/caac.21565.
[18]	Han B, Li K, Zhao Y，et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer：a multicentre，randomised phase Ⅱ trial（ALTER0302）[J]. Br J Cancer，2018，118(5): 654-661. DOI: 10.1038/bjc.2017.478.
[19]	Han B, Li K, Wang Q，et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer：The ALTER 0303 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol，2018，4(11): 1569-1575. DOI: 10.1001/jamaoncol.2018.3039.
[20]	Chi Y, Fang Z, Hong X，et al. Safety and Efficacy of Anlotinib，a Multikinase Angiogenesis Inhibitor，in Patients with Refractory Metastatic Soft-Tissue Sarcoma[J]. Clin Cancer Res，2018，24(21): 5233-5238. DOI: 10.1158/1078-0432.CCR-17-3766.
[21]	Du L, Wang Y, Sun X，et al. Thyroid cancer：trends in incidence，mortality and clinical-pathological patterns in Zhejiang Province，Southeast China[J]. BMC Cancer，2018，18(1): 291. DOI: 10.1186/s12885-018-4081-7.
[22]	Sun Y, Du F, Gao M，et al. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer[J]. Thyroid，2018，28(11): 1455-1461. DOI: 10.1089/thy.2018.0022.
[23]	Miyake H, Matsushita Y, Watanabe H，et al. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma[J]. Med Oncol，2018，35(10): 133. DOI: 10.1007/s12032-018-1195-3.
[24]	Zhou AP, Bai Y, Song Y，et al. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma：A Randomized PhaseⅡ Clinical Trial[J]. Oncologist，2019，24(8): e702-e708. DOI: 10.1634/theoncologist.2018-0839.
[25]	Miao C, Cao J, Wang Y，et al. Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib：a systematic review and meta-analysis[J]. Oncotarget，2017，8(40): 68854-68862. DOI: 10.18632/oncotarget.19924.
[26]	Si X, Zhang L, Wang H，et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer：Experiences in ALTER-0303[J]. Thorac Cancer，2019，10(3): 551-556. DOI: 10.1111/1759-7714.12977.
[27]	Lee SH, Bang YJ, Mainwaring P，et al. Sunitinib in metastatic renal cell carcinoma：an ethnic Asian subpopulation analysis for safety and efficacy[J]. Asia Pac J Clin Oncol，2014，10(3): 237-245. DOI: 10.1111/ajco.12163.
[28]	Cheng AL, Kang YK, Chen Z，et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma：a phaseⅢ randomised，double-blind，placebo-controlled trial[J]. Lancet Oncol，2009，10(1): 25-34. DOI: 10.1016/s1470-2045(08)70285-7.
[29]	Jiang L, Xiao J. 2-phenylethynesulfonamide inhibits growth of oral squamous cell carcinoma cells by blocking the function of heat shock protein 70[J]. Biosci Rep，2020，40(3): BSR2020 0079. DOI: 10.1042/BSR20200079.
[30]	Thavarool SB, Muttath G, Nayanar S，et al. Improved survival among oral cancer patients：findings from a retrospective study at a tertiary care cancer centre in rural Kerala，India[J]. World J Surg Oncol，2019，17(1): 15. DOI: 10.1186/s12957-018-1550-z.
[31]	Petti S, Scully C. How many individuals must be screened to reduce oral cancer mortality rate in the Western context？A challenge[J]. Oral Dis，2015，21(8): 949-954. DOI: 10.1111/odi.12372.
[32]	Minhas S, Kashif M, Altaf W，et al. Concomitant-chemoradiotherapy-associated oral lesions in patients with oral squamous-cell carcinoma[J]. Cancer Biol Med，2017，14(2): 176-182. DOI: 10.20892/j.issn.2095-3941.2016.0096.
[33]	Srivastava S, Mohammad S, Gupta S，et al. Chemoprotective effect of nanocurcumin on 5-fluorouracil-induced-toxicity toward oral cancer treatment[J]. Natl J Maxillofac Surg，2018，9(2): 160-166. DOI: 10.4103/njms.NJMS_27_18.
[34]	Patil VM, Noronha V, Joshi A，et al. PhaseⅠ/Ⅱ Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer[J]. J Clin Oncol，2019，37(32): 3032-3041. DOI: 10.1200/JCO.19.01076.
[35]	Hamauchi S, Yokota T, Mizumachi T，et al. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin[J]. Int J Clin Oncol，2019，24(5): 468-475. DOI: 10.1007/s10147-018-01392-9.
[36]	Hwang-Bo J, Park JH, Bae MG，et al. Recombinant canstatin inhibits VEGF-A-induced lymphangiogenesis and metastasis in an oral squamous cell carcinoma SCC-Ⅶ animal model[J]. Cancer Med，2016，5(10): 2977-2988. DOI: 10.1002/cam4.866.
[37]	Lin X, Khalid S, Qureshi MZ，et al. VEGF mediated signaling in oral cancer[J]. Cell Mol Biol（Noisy-le-grand），2016，62(14): 64-68. DOI: 10.14715/cmb/2016.62.14.11.
[38]	Pianka A, Knösel T, Probst FA，et al. Vascular endothelial growth factor receptor isoforms：are they present in oral squamous cell carcinoma？[J]. J Oral Maxillofac Surg，2015，73(5): 897-904. DOI: 10.1016/j.joms.2014.12.030.
[39]	Lin YW, Huang ST, Wu JC，et al. Novel HDGF/HIF-1alpha/VEGF axis in oral cancer impacts disease prognosis[J]. BMC Cancer，2019，19(1): 1083. DOI: 10.1186/s12885-019-6229-5.
[40]	Xie X, Wang Z, Chen F，et al. Roles of FGFR in oral carcinogenesis[J]. Cell Prolif，2016，49(3): 261-269. DOI: 10.1111/cpr.12260.
[41]	Ong HS, Gokavarapu S, Tian Z，et al. PDGFRA mRNA overexpression is associated with regional metastasis and reduced survival in oral squamous cell carcinoma[J]. J Oral Pathol Med，2018，47(7): 652-659. DOI: 10.1111/jop.12713.
[42]	Chu C, Shang W, Sun Y，et al. Anlotinib is effective in patients with advanced oral cancer？[J]. Med Hypotheses，2020，137: 109578. DOI: 10.1016/j.mehy.2020.109578.
[43]	Syed YY. Anlotinib：First Global Approval[J]. Drugs，2018，78(10): 1057-1062. DOI: 10.1007/s40265-018-0939-x.
[44]	Sánchez-Danés A, Blanpain C. Deciphering the cells of origin of squamous cell carcinomas[J]. Nat Rev Cancer，2018，18(9): 549-561. DOI: 10.1038/s41568-018-0024-5.
[45]	Deng Y, Zhong ZY, Tan XR，et al. Satisfactory short-term outcome after anlotinib and docetaxel chemotherapy in tongue cancer with N3 cervical lymph node metastasis：A case report [J]. Clin Case Rep，2019，7(10): 1923-1927. DOI: 10.1002/ccr3.2390.
[46]	牛志成，何东伟，汪治宇.抗血管生成药物联合免疫检查点抑制剂治疗恶性肿瘤的研究进展[J].中国肿瘤生物治疗杂志，2019，26(9): 1012-1018. DOI: 10.3872/j.issn.1007-385x.2019.09.013.
[47]	Larkins E, Blumenthal GM, Yuan WS，et al. FDA Approval Summary：Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy[J]. Oncologist，2017，22(7): 873-878. DOI: 10.1634/theoncologist.2016-0496.

临床试验注册号		研究阶段	治疗方案顺序	对照组	人数	PFS[月，中位数(95% CI)]	OS[月，中位数(95% CI)]	ORR(%)	治疗相关
临床试验注册号		研究阶段	治疗方案顺序	对照组	人数	PFS[月，中位数(95% CI)]	OS[月，中位数(95% CI)]	ORR(%)	调整剂量人数(%)	死亡人数(%)
晚期非小细胞肺癌		?	?	?	?	?	?	?	?	?
?	NCT01924195^[18]	Ⅱ期	3线及以上	安慰剂	117	4.8(3.5 ~ 6.4)VS 1.2(0.7 ~ 1.6), P<0.001	9.3(6.8 ~ 15.1)VS 6.3(4.3 ~ 10.5), P = 0.232	10.0 VS 0.0,P = 0.028	10.0	0.0
?	NCT02388919^[19]	Ⅲ期	3线及以上	安慰剂	439	5.4(4.4 ~ 5.6)VS 1.4(1.1 ~ 1.5), P<0.001	9.6(8.2 ~ 10.6)VS 6.3(5.0 ~ 8.1), P = 0.002	9.2 VS 0.7,P<0.001	8.9	-
晚期软组织肉瘤		?	?	?	?	?	?	?	?	?
?	NCT01878448^[20]	Ⅱ期	NR	-	166	5.6(4.4 ~ 7.7)	12.0(11.0 ~ 16.0)	13.0	14.5	0.0
晚期髓样甲状腺癌		?	?	?	?	?	?	?	?	?
?	NCT01874873^[22]	Ⅱ期	NR	-	58	-	-	56.9	20.7	-
转移性肾细胞癌		?	?	?	?	?	?	?	?	?
?	NCT02072031^[24]	Ⅱ期	1线	Sunitinib	133	17.5 VS 16.6,P>0.05	30.9 VS 30.5,P>0.05	30.3 VS 27.9,P>0.05	7.8 VS 16.3，P = 0.14	-

临床试验注册号		研究阶段	治疗方案顺序	对照组	人数	PFS[月，中位数(95% CI)]	OS[月，中位数(95% CI)]	ORR(%)	治疗相关
临床试验注册号		研究阶段	治疗方案顺序	对照组	人数	PFS[月，中位数(95% CI)]	OS[月，中位数(95% CI)]	ORR(%)	调整剂量人数(%)	死亡人数(%)
晚期非小细胞肺癌		?	?	?	?	?	?	?	?	?
?	NCT01924195^[18]	Ⅱ期	3线及以上	安慰剂	117	4.8(3.5 ~ 6.4)VS 1.2(0.7 ~ 1.6), P<0.001	9.3(6.8 ~ 15.1)VS 6.3(4.3 ~ 10.5), P = 0.232	10.0 VS 0.0,P = 0.028	10.0	0.0
?	NCT02388919^[19]	Ⅲ期	3线及以上	安慰剂	439	5.4(4.4 ~ 5.6)VS 1.4(1.1 ~ 1.5), P<0.001	9.6(8.2 ~ 10.6)VS 6.3(5.0 ~ 8.1), P = 0.002	9.2 VS 0.7,P<0.001	8.9	-
晚期软组织肉瘤		?	?	?	?	?	?	?	?	?
?	NCT01878448^[20]	Ⅱ期	NR	-	166	5.6(4.4 ~ 7.7)	12.0(11.0 ~ 16.0)	13.0	14.5	0.0
晚期髓样甲状腺癌		?	?	?	?	?	?	?	?	?
?	NCT01874873^[22]	Ⅱ期	NR	-	58	-	-	56.9	20.7	-
转移性肾细胞癌		?	?	?	?	?	?	?	?	?
?	NCT02072031^[24]	Ⅱ期	1线	Sunitinib	133	17.5 VS 16.6,P>0.05	30.9 VS 30.5,P>0.05	30.3 VS 27.9,P>0.05	7.8 VS 16.3，P = 0.14	-

药品	不同点	相似点
安罗替尼	1.对VEGFR-2/3选择性较强，抑制肿瘤血管生成能力较强	1.作用机制相似，与VEGFR等血管生成因子受体结合，抑制肿瘤血管生成2.结合靶点较多，干扰多条信号通路，不良反应（高血压、手足综合征等）较多
	2.不良反应大多可缓解，腹泻发生率相对较低
	3.易发生血脂升高、甘油三酯升高，需监测血压、血脂等指标
索拉菲尼、舒尼替尼等	1.与VEGFR结合能力相对较弱，抑制肿瘤血管生成能力较弱
	2.腹泻发生率相对较高
	3.血脂升高、甘油三酯升高发生率相对较低

药品	不同点	相似点
安罗替尼	1.对VEGFR-2/3选择性较强，抑制肿瘤血管生成能力较强	1.作用机制相似，与VEGFR等血管生成因子受体结合，抑制肿瘤血管生成2.结合靶点较多，干扰多条信号通路，不良反应（高血压、手足综合征等）较多
	2.不良反应大多可缓解，腹泻发生率相对较低
	3.易发生血脂升高、甘油三酯升高，需监测血压、血脂等指标
索拉菲尼、舒尼替尼等	1.与VEGFR结合能力相对较弱，抑制肿瘤血管生成能力较弱
	2.腹泻发生率相对较高
	3.血脂升高、甘油三酯升高发生率相对较低

Please choose a citation manager

Content to export